Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Pediatric Cardiology
Erschienen in: Pediatric Cardiology 4/2012

01.04.2012 | Review Article

Review of Inhaled Nitric Oxide in the Pediatric Cardiac Surgery Setting

verfasst von: Paul A. Checchia, Ronald A. Bronicki, Brahm Goldstein

Erschienen in: Pediatric Cardiology | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Surgical intervention for congenital heart disease (CHD) can be complicated by pulmonary hypertension (PH), which increases morbidity, mortality, and medical burden. Consequently, postoperative management of PH is an important clinical consideration to improve outcomes. Inhaled nitric oxide (iNO) is a widely accepted standard of care for PH and has been studied in the context of cardiac surgery for CHD. However, large randomized, double-blind, placebo-controlled, multicenter clinical trials in pediatric patients are limited. This review will provide an overview of the clinical studies in this setting and will discuss general treatment considerations to facilitate a better understanding of the clinical use of iNO for PH after pediatric cardiac surgery.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
2.
Atz AM, Wessel DL (1999) Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology 91:307–310PubMedCrossRef
3.
Bacha EA et al (2000) Management of pulmonary arteriovenous malformations after surgery for complex congenital heart disease. J Thorac Cardiovasc Surg 119:175–176PubMedCrossRef
4.
Beghetti M et al (1995) Continuous low dose inhaled nitric oxide for treatment of severe pulmonary hypertension after cardiac surgery in paediatric patients. Br Heart J 73:65–68PubMedCrossRef
5.
Beghetti M et al (1998) Decreased exhaled nitric oxide may be a marker of cardiopulmonary bypass-induced injury. Ann Thorac Surg 66:532–534PubMedCrossRef
6.
Behrends M, Beiderlinden M, Peters J (2005) Combination of sildenafil and bosentan for nitric oxide withdrawal. Eur J Anaesthesiol 22:155–157PubMedCrossRef
7.
Botha P et al (2007) Inhaled nitric oxide for modulation of ischemia-reperfusion injury in lung transplantation. J Heart Lung Transplant 26:1199–1205PubMedCrossRef
8.
Brown KL et al (2003) Risk factors for long intensive care unit stay after cardiopulmonary bypass in children. Crit Care Med 31:28–33PubMedCrossRef
9.
Carmona MJ, Auler JO Jr (1998) Effects of inhaled nitric oxide on respiratory system mechanics, hemodynamics, and gas exchange after cardiac surgery. J Cardiothorac Vasc Anesth 12:157–161PubMedCrossRef
10.
Costard-Jackle A, Fowler MB (1992) Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. J Am Coll Cardiol 19:48–54PubMedCrossRef
11.
Crosswhite P, Sun Z (2010) Nitric oxide, oxidative stress and inflammation in pulmonary arterial hypertension. J Hypertens 28:201–212PubMedCrossRef
12.
Curran RD et al (1995) Inhaled nitric oxide for children with congenital heart disease and pulmonary hypertension. Ann Thorac Surg 60:1765–1771PubMedCrossRef
13.
Daftari B, Alejos JC, Perens G (2010) Initial experience with sildenafil, bosentan, and nitric oxide for pediatric cardiomyopathy patients with elevated pulmonary vascular resistance before and after orthotopic heart transplantation. J Transplant 2010:1–6CrossRef
14.
Davidson D et al (1999) Safety of withdrawing inhaled nitric oxide therapy in persistent pulmonary hypertension of the newborn. Pediatrics 104:231–236PubMedCrossRef
15.
Day RW et al (2000) Randomized controlled study of inhaled nitric oxide after operation for congenital heart disease. Ann Thorac Surg 69:1907–1912PubMedCrossRef
16.
El Kebir D et al (2005) Effects of inhaled nitric oxide on inflammation and apoptosis after cardiopulmonary bypass. Chest 128:2910–2917PubMedCrossRef
17.
Elahi MM et al (2009) Inspired nitric oxide and modulation of oxidative stress during cardiac surgery. Curr Drug Saf 4:188–198PubMedCrossRef
18.
Fullerton DA et al (1996) Effective control of pulmonary vascular resistance with inhaled nitric oxide after cardiac operation. J Thorac Cardiovasc Surg 111:753–762PubMedCrossRef
19.
Gamillscheg A et al (1997) Inhaled nitric oxide in patients with critical pulmonary perfusion after Fontan-type procedures and bidirectional Glenn anastomosis. J Thorac Cardiovasc Surg 113:435–442PubMedCrossRef
20.
Gianetti J et al (2004) Supplemental nitric oxide and its effect on myocardial injury and function in patients undergoing cardiac surgery with extracorporeal circulation. J Thorac Cardiovasc Surg 127:44–50PubMedCrossRef
21.
Giglia TM, Humpl T (2010) Preoperative pulmonary hemodynamics and assessment of operability: Is there a pulmonary vascular resistance that precludes cardiac operation? Pediatr Crit Care Med 11:S57–S69PubMedCrossRef
22.
Gladwin MT, Crawford JH, Patel RP (2004) The biochemistry of nitric oxide, nitrite, and hemoglobin: Role in blood flow regulation. Free Radic Biol Med 36:707–717PubMedCrossRef
23.
Goldman AP et al (1996) Pharmacological control of pulmonary blood flow with inhaled nitric oxide after the fenestrated Fontan operation. Circulation 94:II44–II48PubMed
24.
Gothberg S, Edberg KE (2000) Inhaled nitric oxide to newborns and infants after congenital heart surgery on cardiopulmonary bypass: a dose-response study. Scand Cardiovasc J 34:154–158PubMedCrossRef
25.
Hamon I et al (2010) Methaemoglobinaemia risk factors with inhaled nitric oxide therapy in newborn infants. Acta Paediatr 99:1467–1473PubMedCrossRef
26.
Hawkins A, Tulloh R (2009) Treatment of pediatric pulmonary hypertension. Vasc Health Risk Manag 5:509–524PubMed
27.
Haydar A et al (1992) Inhaled nitric oxide for postoperative pulmonary hypertension in patients with congenital heart defects. Lancet 340:1545PubMedCrossRef
28.
Hermon M et al (1999) Intravenous prostacyclin mitigates inhaled nitric oxide rebound effect: A case control study. Artif Organs 23:975–978PubMedCrossRef
29.
Hermon MM et al (2003) Methemoglobin formation in children with congenital heart disease treated with inhaled nitric oxide after cardiac surgery. Intensive Care Med 29:447–452PubMed
30.
31.
Hofer A et al (2002) Successful management of severe life-threatening hypoxemia due to pulmonary arteriovenous malformation. Anesthesiology 97:1313–1315PubMedCrossRef
32.
Hoffman JI, Kaplan S (2002) The incidence of congenital heart disease. J Am Coll Cardiol 39:1890–1900PubMedCrossRef
33.
Hopkins RA et al (1991) Pulmonary hypertensive crises following surgery for congenital heart defects in young children. Eur J Cardiothorac Surg 5:628–634PubMedCrossRef
34.
Hoskote A et al (2010) Acute right ventricular failure after pediatric cardiac transplant: predictors and long-term outcome in current era of transplantation medicine. J Thorac Cardiovasc Surg 139:146–153PubMedCrossRef
35.
INOmax [package insert] (2010) INO Therapeutics, Clinton, NJ
36.
Ivy DD et al (1998) Dipyridamole attenuates rebound pulmonary hypertension after inhaled nitric oxide withdrawal in postoperative congenital heart disease. J Thorac Cardiovasc Surg 115:875–882PubMedCrossRef
37.
Journois D et al (1994) Inhaled nitric oxide as a therapy for pulmonary hypertension after operations for congenital heart defects. J Thorac Cardiovasc Surg 107:1129–1135PubMed
38.
Journois D et al (2005) Effects of inhaled nitric oxide administration on early postoperative mortality in patients operated for correction of atrioventricular canal defects. Chest 128:3537–3544PubMedCrossRef
39.
Khambadkone S et al (2003) Basal pulmonary vascular resistance and nitric oxide responsiveness late after Fontan-type operation. Circulation 107:3204–3208PubMedCrossRef
40.
Klinger JR (2007) The nitric oxide/cGMP signaling pathway in pulmonary hypertension. Clin Chest Med 28:143–167PubMedCrossRef
41.
Kumar VH et al (2010) Exposure to supplemental oxygen and its effects on oxidative stress and antioxidant enzyme activity in term newborn lambs. Pediatr Res 67:66–71PubMedCrossRef
42.
Lang JD Jr et al (2007) Inhaled NO accelerates restoration of liver function in adults following orthotopic liver transplantation. J Clin Invest 117:2583–2591PubMedCrossRef
43.
Lee JE, Hillier SC, Knoderer CA (2008) Use of sildenafil to facilitate weaning from inhaled nitric oxide in children with pulmonary hypertension following surgery for congenital heart disease. J Intensive Care Med 23:329–334PubMedCrossRef
44.
Magazine HI et al (2000) Rebound from nitric oxide inhibition triggers enhanced monocyte activation and chemotaxis. J Immunol 165:102–107PubMed
45.
McLaughlin VV et al (2009) ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on expert consensus documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 119:2250–2294PubMedCrossRef
46.
Meade MO et al (2003) A randomized trial of inhaled nitric oxide to prevent ischemia-reperfusion injury after lung transplantation. Am J Respir Crit Care Med 167:1483–1489PubMedCrossRef
47.
Miller OI et al (1994) Very-low-dose inhaled nitric oxide: a selective pulmonary vasodilator after operations for congenital heart disease. J Thorac Cardiovasc Surg 108:487–494PubMed
48.
Miller OI et al (1995) Rebound pulmonary hypertension on withdrawal from inhaled nitric oxide. Lancet 346:51–52PubMedCrossRef
49.
Miller OI et al (2000) Inhaled nitric oxide and prevention of pulmonary hypertension after congenital heart surgery: a randomised double-blind study. Lancet 356:1464–1469PubMedCrossRef
50.
Morris K et al (2000) Comparison of hyperventilation and inhaled nitric oxide for pulmonary hypertension after repair of congenital heart disease. Crit Care Med 28:2974–2978PubMedCrossRef
51.
Mychaskiw G, Sachdev V, Heath BJ (2001) Sildenafil (viagra) facilitates weaning of inhaled nitric oxide following placement of a biventricular-assist device. J Clin Anesth 13:218–220PubMedCrossRef
52.
Namachivayam P et al (2006) Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. Am J Respir Crit Care Med 174:1042–1047PubMedCrossRef
53.
Pagowska-Klimek I et al. (2011) Predictors of long intensive care unit stay following cardiac surgery in children. Eur J Cardiothorac Surg 40: 179–184
54.
Pearl JM et al (2002) Inhaled nitric oxide increases endothelin-1 levels: a potential cause of rebound pulmonary hypertension. Crit Care Med 30:89–93PubMedCrossRef
55.
Radomski MW, Moncada S (1993) Regulation of vascular homeostasis by nitric oxide. Thromb Haemost 70:36–41PubMed
56.
Reiter CD et al (2002) Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 8:1383–1389PubMedCrossRef
57.
Rich GF et al (1993) Inhaled nitric oxide. Selective pulmonary vasodilation in cardiac surgical patients. Anesthesiology 78:1028–1035PubMedCrossRef
58.
Rosenzweig EB, Widlitz AC, Barst RJ (2004) Pulmonary arterial hypertension in children. Pediatr Pulmonol 38:2–22PubMedCrossRef
59.
Russell IA et al (1998) The effects of inhaled nitric oxide on postoperative pulmonary hypertension in infants and children undergoing surgical repair of congenital heart disease. Anesth Analg 87:46–51PubMed
60.
Sato H et al (1997) Basal nitric oxide expresses endogenous cardioprotection during reperfusion by inhibition of neutrophil-mediated damage after surgical revascularization. J Thorac Cardiovasc Surg 113:399–409PubMedCrossRef
61.
Schulze-Neick I et al (2001) Pulmonary vascular resistance after cardiopulmonary bypass in infants: effect on postoperative recovery. J Thorac Cardiovasc Surg 121:1033–1039PubMedCrossRef
62.
Shimpo H et al (1997) Inhaled low-dose nitric oxide for postoperative care in patients with congenital heart defects. Artif Organs 21:10–13PubMedCrossRef
63.
Suesaowalak M, Cleary JP, Chang AC (2010) Advances in diagnosis and treatment of pulmonary arterial hypertension in neonates and children with congenital heart disease. World J Pediatr 6:13–31PubMedCrossRef
64.
Tang JR et al (2007) Early inhaled nitric oxide treatment decreases apoptosis of endothelial cells in neonatal rat lungs after vascular endothelial growth factor inhibition. Am J Physiol Lung Cell Mol Physiol 293:L1271–L1280PubMedCrossRef
65.
Tulloh RM (2005) Congenital heart disease in relation to pulmonary hypertension in paediatric practice. Paediatr Respir Rev 6:174–180PubMedCrossRef
66.
Turanlahti MI, Laitinen PO, Pesonen EJ (2000) Preoperative and postoperative response to inhaled nitric oxide. Scand Cardiovasc J 34:46–52PubMedCrossRef
67.
Urcelay GE et al (2005) Nitric oxide in pulmonary arteriovenous malformations and Fontan procedure. Ann Thorac Surg 80:338–340PubMedCrossRef
68.
Vinten-Johansen J et al (1999) Nitric oxide and the vascular endothelium in myocardial ischemia-reperfusion injury. Ann N Y Acad Sci 874:354–370PubMedCrossRef
69.
Wessel DL et al (1993) Use of inhaled nitric oxide and acetylcholine in the evaluation of pulmonary hypertension and endothelial function after cardiopulmonary bypass. Circulation 88:2128–2138PubMed
70.
Yahagi N et al (1994) Inhaled nitric oxide for the postoperative management of Fontan-type operations. Ann Thorac Surg 57:1371–1373PubMedCrossRef
71.
Yoshimura N et al (2005) Inhaled nitric oxide therapy after Fontan-type operations. Surg Today 35:31–35PubMedCrossRef
72.
Zobel G et al (1998) Inhaled nitric oxide in infants and children after open heart surgery. J Cardiovasc Surg (Torino) 39:79–86
Metadaten
Titel
Review of Inhaled Nitric Oxide in the Pediatric Cardiac Surgery Setting
verfasst von
Paul A. Checchia
Ronald A. Bronicki
Brahm Goldstein
Publikationsdatum
01.04.2012
Verlag
Springer-Verlag
Erschienen in
Pediatric Cardiology / Ausgabe 4/2012
Print ISSN: 0172-0643
Elektronische ISSN: 1432-1971
DOI
https://doi.org/10.1007/s00246-012-0172-4

Weitere Artikel der Ausgabe 4/2012

Pediatric Cardiology 4/2012 Zur Ausgabe

Case Report

Congenital Long-QT Syndrome in Addison’s Disease: A Novel Association

Images in Pediatric Cardiology

Pulmonary Vein Atresia with Severe Contralateral Pulmonary Vein Stenosis in a Child

Original Article

Functional Echocardiographic Assessment of Myocardial Performance in Anemic Premature Infants: A Pilot Study

Case Report

Primary Cardiac Leiomyoma of the Ventricular Septum: A Rare Form of Pediatric Intracardiac Tumor

Original Article

Risk Factors Associated With Morbidity and Mortality After Pulmonary Valve Replacement in Adult Patients With Previously Corrected Tetralogy of Fallot

Original Article

Mitral Valve Replacement Using Mechanical Prostheses in Children: Early and Long-Term Outcomes

Neu im Fachgebiet Kardiologie

Ist Fasten vor Koronarinterventionen wirklich nötig?

04.06.2024 Interventionelle Verfahren in der Kardiologie Nachrichten

Wenn Eingriffe wie eine Koronarangiografie oder eine Koronarangioplastie anstehen, wird häufig empfohlen, in den Stunden zuvor nüchtern zu bleiben. Ein französisches Forscherteam hat diese Maßnahme hinterfragt.

PET kann infarktgefährdete Koronararterien entdecken

04.06.2024 Koronare Herzerkrankung Nachrichten

Der Nachweis aktiver Plaques mittels 18F-Natriumfluorid-PET hilft nicht nur, infarktgefährdete Patienten, sondern auch infarktgefährdete Koronararterien zu erkennen. Von einer gezielten Behandlung vulnerabler Plaques ist man trotzdem weit entfernt.

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

03.06.2024 Semaglutid Nachrichten

Der GLP-1-Agonist Semaglutid hat in der FLOW-Studie bewiesen, dass sich damit die Progression chronischer Nierenerkrankungen bei Patienten mit Typ-2-Diabetes bremsen lässt. Auch in kardiovaskulärer Hinsicht war die Therapie erfolgreich.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise